Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus Vinorelbine in HER2-positive Advanced Breast Cancer
NCT04903652Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jan 2021; status: completed.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04903652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903652.